Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-03-07
2006-03-07
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S001110, C536S021000, C536S123100, C536S124000
Reexamination Certificate
active
07008933
ABSTRACT:
A process for prophylaxis and therapy of thrombotic processes includes preparing heparin having an average molecular weight ranging from 10 to 11.5 kd; formulating a pharmaceutical preparation which includes the heparin; and employing the pharmaceutical preparation for prophylaxis and therapy of thrombotic processes. Preferably the heparin has an average molecular weight of 10.5 kd.
REFERENCES:
Ekre, Hans-Peter T. “Inhibition Of Human And Guinea Pig Complement By Heparin Fractions Differing In Affinity For Antithrombin III Or In Average Molecular Weight”, International Journal of Immunopharmacology, 1985, 7(2), 271-280.
Alban et al., “The Anticoagulatory Impact of Low-Molecular-Weight Heparins is Subject to Product-specific Endogenous Modulation. The Significance of TFPI Release and Profibrinalytic Effect”, American Congress of Cardiology, Orlando, Florida 1997.
Fareed et al., “Low molecular weight heparins: a development perspective”, Abstract, Ashley Publications Ltd., ISSN 1354-3783—1997.
Fareed et al., “Biochemical and Pharmacologic Inequivalence of Low Molecular Weight Heparins”, Annuals New York Academy of Science (1989) 556, pp. 333-353.
Nader et al., “Preclinical Differentiation of Low Molecular Weight Heparins”, Seminars in Thrombosis and Hemostasis—vol. 25, Suppl. 3, 1999, pp. 63-72.
Fareed, “Antithrombotic Drugs in Traumatic Disorders Newer Developments and Future Perspectives”, International Symposium 1992.
Boneu, “Low Molecular Weight Heparins: Are They Superior to Unfractionated Heparins to Prevent and to Treat Deep Vein Thrombosis”,Trombosis Research, 100 (2000), V113-V120.
Sandset, “The Role of Tissue Factor Pathway Inhibitor as a Physiological Anticoagulant”, 15thIntnl. Congress on Trhombosis (1998), pp. 183-189.
Wessler, M.D., “Thrombosis in the Presence of Vascular Statis”,American Journal of Medicine, 1962, vol. 33, pp. 648-666.
Hirsh et al., “Low Molecular Weight Heparins”,The Journal of The American Society of Hematology, vol. 79, No. 1, Jan. 1, 1992, pp. 1-17.
Kandrotas, “Heparin Pharmacokinetics and Pharmacodynamics”,Clin. Pharmacokinet, 22(5); pp. 359-374, 1992.
Fareed et al., “Studies on the Antithrombotic Effects and Pharmacokinetics of Heparin Fractions and Fragments”,Seminars in Thrombosis and Hemostasis, vol. 11, No. 1, (1985).
WO 01 02443—“Heparin Compositions That Inhibit Clot Associated Coagulation Factors”, Jack Hirsh, Publication date: Jan. 11, 2001.
“Inhibition of Human and Guinea Pig Complement by Heparin Fractions Differing in Affinity for Antithrombin III Or In Average Molecular Weight”, Hans-Peter T. Ekre, Researach and Development, Stockholm Sweden, pp. 271-277.
Kaiser et al., “Preclinical Biochemistry and Pharmacology of Low Molecular Weight Heparins in Vivo-Studies of Venous and Arterial Thrombosis”, Seminars in Thrombosis and Hemostasis, vol. 25, Suppl 3, (1999), pp. 35-42.
Alban et al., “Plasma Levels of total and Free Tissue Factor Pathway Inhibitor (TFPI) as Individual Pharmacological Parameters of Various Heparins”, Thromb Haemost 2001; 85; pp. 824-829.
GLYCODesign, Inc., Pharmaceutical and Biotechnology Companies, NetSci: The Biotech Yellow Pages, Seite 1, von 2, glycodesign.html.
Krishnan Ganapathy
Venable LLP
Wilson James O.
Wiseman Thomas G.
LandOfFree
Process for prophylaxis and therapy of thrombotic processes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for prophylaxis and therapy of thrombotic processes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for prophylaxis and therapy of thrombotic processes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586469